Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
14 mars 2023 16h05 HE
|
Decibel Therapeutics, Inc.
- Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the...
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
16 févr. 2023 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
09 févr. 2023 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
24 janv. 2023 07h00 HE
|
Decibel Therapeutics, Inc.
The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of...
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
09 nov. 2022 16h45 HE
|
Decibel Therapeutics, Inc.
- Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss - - Announced Submission of CTAs...
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
02 nov. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
17 oct. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory...
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
12 oct. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
22 sept. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
20 sept. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...